Charles River Laboratories International, Inc. (CRL) closed Thursday at $342.63, declining 0.95% over the prior 24-hour period. The single-session pullback came amid an otherwise constructive recent stretch for the stock.
Over the past seven days, CRL has gained 5.04%, reflecting a broader trend of strengthening momentum. The 30-day performance is more pronounced, with shares rising 13.34% over that window and lifting the company's market capitalization to $16.57 billion.
The daily dip represents a modest pause in what has been a notable run for the contract research organization. Thursday's move leaves the stock well above where it traded a month ago, underscoring the magnitude of the recent advance.
Charles River Laboratories, which provides drug development and safety testing services, continues to draw attention from market participants tracking the broader life sciences sector. The latest session's decline did little to erase the gains accumulated over the preceding weeks.
